Czech medtech startup Kardi AI raises €5.3M Series A to launch in Germany, India, UAE

Czech medtech startup Kardi AI has raised €5.3 million in a Series A round led by German healthtech fund Callisto Health. The round values the company at €23 million. According to the company, it is the largest round a Czech medtech startup has raised to date.

Česká spořitelna and Slovenská sporiteľňa joined through their corporate venture programmes, both operating under the Seed Starter name. Earlier backers BrightCap Ventures, Purple Ventures, DEPO Ventures and Garage Angels also put in money.

The company plans to use the funding to enter new markets in Europe and Asia and to develop models that estimate the risk of cardiac arrhythmias. Germany is the main European target, followed by India and the UAE.

Kardi AI makes a fitness chest strap with a built-in ECG sensor that connects to a mobile app, where AI analyses the recordings. Users wear it during their normal day, see the results and can pass them to their doctor.

Monitoring over longer periods makes it possible to catch intermittent arrhythmias, which often go unnoticed during a short check-up at a clinic. The system does not make a diagnosis. The company positions it as a source of data that helps physicians decide on further care.

Kardi AI was founded in Olomouc in 2022. In the Czech Republic it works with more than 70 hospitals and over 20 corporate and employee-benefit partners, and more than 6,000 people use its technology. It also operates in Slovakia, Poland, Romania and Bulgaria, and has completed pilot projects in Germany, where it is preparing to launch.

In July 2026, the company received an MD-15 import licence from India’s regulator CDSCO, covering both its hardware and software. The Indian launch will start in Hyderabad, where Kardi AI is in talks with healthcare partners and finalising its commercial and logistics setup. Operations there are planned to begin in the last quarter of 2026.

In the UAE, it holds a Medical Device Registration Certificate from the Ministry of Health and Prevention. It is also finishing medical device approval in Singapore, which it plans to use as an entry point to Southeast Asia.

”We are gradually moving beyond detecting heart rhythm disorders towards technology capable of identifying an increased risk before arrhythmia manifests. Nearly two billion people live in the markets where we already operate or are preparing to launch,” said Vlastimil Hrabal, co-founder and CEO of Kardi AI.